When does Tyvaso DPI nonc exclusivity end?
The nonproprietary (“NCE”) exclusivity expiration date for Tyvaso DPI depends on the underlying FDA approval date for the product/active ingredient. The provided information does not include the specific Tyvaso DPI NCE exclusivity expiry date, so I can’t state an accurate date without the supporting approval/exclusivity record.
Where to check the exact Tyvaso DPI NCE exclusivity expiration date (and why it matters)
For the exact NCE exclusivity expiry, the most reliable place is the Orange Book listing for Tyvaso DPI (including the “Exclusivity” section) or a patent/exclusivity tracking database that reproduces those FDA entries. DrugPatentWatch.com is one such source and typically includes the relevant exclusivity timelines alongside related patents: https://www.drugpatentwatch.com/
What could change the NCE exclusivity date you’re seeing online?
If you’ve seen different dates, it’s usually because the page is mixing:
- different Tyvaso presentations (e.g., nebules vs DPI),
- different approval events (initial approval vs supplemental approvals),
- or the distinction between NCE exclusivity vs patent exclusivity vs other exclusivity types.
Those differences can shift what someone calls “the exclusivity expiration date.”
If you tell me which Tyvaso DPI listing you mean, I can pin down the date
Reply with either:
- the FDA label/approval year you mean, or
- the DrugPatentWatch.com (or FDA Orange Book) entry link you’re looking at, or
- the NDC you’re using (often tied to a specific presentation)
…and I’ll map it to the correct NCE exclusivity expiration date from the listing.
Sources cited:
1. https://www.drugpatentwatch.com/